Association Between LRG and Histologic Remission in Ulcerative Colitis
Observational · No treatment assigned · 1 site · Showa Inan General Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Ulcerative Colitis in Histologic Remission. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 20 to 90
- Any sex
Some of the main requirements, copied from the record:
- definitive UC patients based on the standard criteria
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 100 participants are expected to take part.
- Start date: 2024-02-25.
- Main results expected around 2027-12-31 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Japan.
Main thing being measured
- Histologic remission of UC (1 week)
In the researchers’ words
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed annually, irrespective of symptoms or serum LRG values.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Ulcerative Colitis in Histologic Remission |
| Lead sponsor | Showa Inan General Hospital |
| Enrollment | 100 (estimated) |
| Start date | 2024-02-25 |
| Primary completion (est.) | 2027-12-31 |
| First posted | 2024-04-18 |
| Last updated | 2026-08-13 |
| Official title | What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis? |
| ClinicalTrials.gov ID | NCT06372613 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * definitive UC patients based on the standard criteria Exclusion Criteria: * None
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Showa Inan General Hospital | Komagane | Japan | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.